Targeting transcriptional regulation of SARS-CoV-2 entry factorsACE2andTMPRSS2
Abstract
New therapeutic targets are urgently needed against SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic. Results in this study show that targeting the transcriptional regulation of host entry factorsTMPRSS2andACE2is a viable treatment strategy to prevent SARS-CoV-2 infection. In particular, inhibitors of androgen receptor (AR) or bromodomain and extraterminal domain (BET) proteins are effective against SARS-CoV-2 infection. AR inhibitors are already approved in the clinic for treatment of prostate cancer and are under investigation in COVID-19 patients; BET inhibitors are also in clinical development for other indications and could be rapidly repurposed for COVID-19.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 28, 2020
- Source ID
- 10.1073/pnas.2021450118
Entities
People
- Abhijit Parolia
- Andrew D. Delekta
- Arul Chinnaiyan
- Carla D. Pretto
- Dan R. Robinson
- Fengyun Su
- Gregory Raskind
- Ingrid J. Apel
- Jean Ching-yi Tien
- Jesse W Wotring
- Jonathan Z Sexton
- Lanbo Xiao
- Lisa Mcmurry
- Pushpinder Bawa
- Rahul Mannan
- Rohit Mehra
- Rui Wang
- Sathiya P. Narayanan
- Sethuramasundaram Pitchiaya
- Shaomeng Wang
- Stephanie A. Simko
- Stephanie J. Ellison
- Steven Kregel
- Sylvia Zelenka-wang
- Xiao-Ming Wang
- Xuhong Cao
- Yi-Mi Wu
- Yuanyuan Qiao
- Yunhui Cheng
- Yuping Zhang
- Zejie Mei
Organizations
- National Cancer Institute
- Prostate Cancer Foundation
- United States Department of Defense
- University of Chinese Academy of Sciences
- University of Michigan